Novel oral anticoagulants will recover from slow initial uptake, says analyst

The use of novel oral anticoagulants (NOACs) will see a substantial rise in the anticoagulation market space after an initially sluggish uptake, and will start to be elected over warfarin, the current standard-of-care product in certain indications.

Lakshmi Dharmarajan, research and consulting firm GlobalData's senior analyst covering cardiovascular and metabolic disorders, states that: “NOACs are increasingly being used in patients with venous thromboembolism (VTE) due to the drugs’ rapid onset of action and the ability to be administered in fixed doses without the need for regular coagulation monitoring. Among the VTE population, the fastest to adopt NOACs have been the orthopedic patient segments, for the prevention of deep vein thrombosis (DVT).”

For those with DVT, Xarelto (rivaroxaban, from Bayer [BAYN: DE]) has been demonstrated by real-world studies to have economic advantages over standard-of-care treatments.